Friedreich’s Ataxia is a rare inherited condition that causes progressive problems with balance, coordination, and heart function because the body lacks enough of a protein called frataxin. The study evaluates the drug Nomlabofusp, given as a subcutaneous injection (an injection just under the skin), compared with a placebo that looks identical but contains no active medicine.
The purpose of the study is to find out whether Nomlabofusp can improve movement ability in children and adults with Friedreich’s Ataxia. Participants are randomly assigned to receive either the active medication or the placebo, and neither the participants nor the investigators know which treatment is given. Over roughly a year and a half, participants attend regular clinic visits where they undergo simple tests that measure walking distance, hand coordination, and overall disease severity using a scoring system called the modified Friedreich’s Ataxia Rating Scale, which is explained to participants as a way to track changes in their condition.
Throughout the study, safety is closely watched by recording any side effects, and blood samples are taken to check for immune reactions against the drug. Additional assessments include heart imaging to observe any changes in heart size and measurements of frataxin levels from skin and cheek samples. The study concludes after the final assessment at week 72, at which point the collected data are analyzed to determine the drug’s effectiveness and safety.
France 
